Details

Autor(en) / Beteiligte

• Chocarro, L.
• Blanco, E.
• Arasanz, H.
• Fernández-Rubio, L.
• Bocanegra, A.
• Echaide, M.
• Garnica, M.
• Ramos, P.
• Fernández-Hinojal, G.
• Vera, R.
• Kochan, G.
• Escors, D.

Titel

Clinical landscape of LAG-3-targeted therapy

Ist Teil von

• Immuno-oncology technology, 2022-06, Vol.14, p.100079-100079, Article 100079

Ort / Verlag

Elsevier Ltd

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Lymphocyte-activated gene 3 (LAG-3) is a cell surface inhibitory receptor and a key regulator of immune homeostasis with multiple biological activities related to T-cell functions. LAG-3 is considered a next-generation immune checkpoint of clinical importance, right next to programmed cell death protein 1 (PD-1) and cytotoxic T-cell lymphocyte antigen-4 (CTLA-4). Indeed, it is the third inhibitory receptor to be exploited in human anticancer immunotherapies. Several LAG-3-antagonistic immunotherapies are being evaluated at various stages of preclinical and clinical development. In addition, combination therapies blocking LAG-3 together with other immune checkpoints are also being evaluated at preclinical and clinical levels. Indeed, the co-blockade of LAG-3 with PD-1 is demonstrating encouraging results. A new generation of bispecific PD-1/LAG-3-blocking agents have also shown strong capacities to specifically target PD-1+ LAG-3+ highly dysfunctional T cells and enhance their proliferation and effector activities. Here we identify and classify preclinical and clinical trials conducted involving LAG-3 as a target through an extensive bibliographic research. The current understanding of LAG-3 clinical applications is summarized, and most of the publically available data up to date regarding LAG-3-targeted therapy preclinical and clinical research and development are reviewed and discussed. •LAG-3 is a highly important next-generation immune checkpoint molecule.•Ninety-seven clinical trials are evaluating at least 16 LAG-3-targeting molecules.•Here we identify preclinical and clinical studies conducted involving LAG-3.•Bispecific LAG-3 molecules are being developed, showing strong capacities.•LAG-3/PD-1 co-blockade is demonstrating encouraging results.